ABT
Abbott Laboratories
- Operating income, 2025
- $8.1B
- YoY, 2025
- +18.0%
- 5-year CAGR
- +8.5%
- 10-year CAGR
- +10.9%
Operating income
Operating income by fiscal year
| Period | Operating income | YoY |
|---|---|---|
| 2025 | $8.1B | +18.0% |
| 2024 | $6.8B | +5.4% |
| 2023 | $6.5B | −22.5% |
| 2022 | $8.4B | −0.7% |
| 2021 | $8.4B | +57.3% |
| 2020 | $5.4B | +18.2% |
| 2019 | $4.5B | +24.2% |
| 2018 | $3.7B | +133.4% |
| 2017 | $1.6B | −48.3% |
| 2016 | $3.0B | +5.5% |
| 2015 | $2.9B | +10.3% |
| 2014 | $2.6B | +21.8% |
| 2013 | $2.1B | +56.8% |
| 2012 | $1.4B | −16.5% |
| 2011 | $1.6B | −73.2% |
| 2010 | $6.1B | −2.4% |
| 2009 | $6.2B | +9.5% |
| 2008 | $5.7B | +24.4% |
| 2007 | $4.6B | — |